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Abstract
Background: Dementia is common in end-stage renal disease (ESRD) patients on hemodialysis (HD) and is
associated with worse outcomes. This study aimed to investigate the risk of major adverse cardiac and
cerebrovascular event (MACCE) in elderly patients with dementia initiating HD.
Methods: Using the database from the Health Insurance Review & Assessment Service, we analyzed 10,171 patients
aged 65 years or older who had initiated dialysis from 2005 to 2008. MACCE was defined as a composite outcome
of all-cause mortality, nonfatal acute myocardial infarction, target vessel revascularization, and nonfatal ischemic and
hemorrhagic stroke. The Kaplan-Meier method and Cox proportional hazards model were used, and further
comparisons using propensity-score matching at 1:2 ratio were also performed.
Results: A total of 303 elderly patients (3.0%) had dementia at initiating HD. During follow-up, dementia was a
significant predictor of MACCE after adjustment for confounding variables. In addition, further analyzed in the
propensity-score matched groups, dementia was an independent predictor of both nonfatal ischemic stroke and
all-cause mortality.
Conclusions: Dementia is an independent risk factor for mortality and ischemic stroke in elderly ESRD patients
initiating HD. Patients with dementia who start dialysis should be closely monitored to reduce the risk of mortality
and ischemic stroke.
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Background
Dementia is a syndrome affecting memory, thinking and
social abilities severely enough to interfere with normal
activities of daily living [1]. It is the most common men-
tal disorder in the elderly population and a major cause
of death and disability among elderly individuals in the
general population [2]. The World Health Organization
reports that 47.5 million people have dementia, and
there are 7.7 million new cases every year worldwide [1].
Recent studies revealed that cognitive impairment,
including dementia, is more common in end-stage renal
disease (ESRD) patients than in the general population
[3–7]. This higher prevalence of dementia further deteri-
orates adverse outcomes of the ESRD patients, including
the decline in functional status, hospitalization, dialysis
withdrawal, and mortality [3, 8–10].
As populations are rapidly growing older, accompanied
by the increasing prevalence of diabetes, hypertension,
* Correspondence: drryu@ewha.ac.kr; bluejayway@naver.com
†Equal contributors
1Department of Internal Medicine, College of Medicine, Tissue Injury Defense
Research Center, Ewha Womans University, Seoul, Korea
5Department of Internal Medicine, Yonsei University College of Medicine
Gangnam Severance Hospital, Seoul, Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jung et al. BMC Nephrology  (2017) 18:128 
DOI 10.1186/s12882-017-0547-0
and cardiovascular diseases in most Western countries
[11, 12], the requirement for dialysis treatment is
increasing more rapidly in elderly patients than in youn-
ger ones [6, 13, 14]. Korea is also one of the most rapidly
aging societies in the world. According to the 2014
annual report from the Korean Society of Nephrology –
ESRD registry, the proportion of elderly patients
(>65 years old) among those undergoing dialysis is
markedly increasing, with the proportion rising up to
39.5% [15].
The decision whether and how to initiate dialysis is
always not simple for any ESRD patient; for elderly
patients with dementia, the decision is even more chal-
lenging. Many physicians hesitate to initiate dialysis in
elderly patients with dementia because advanced age
alone is the most important risk factor of death in ESRD
patients [14, 16–18]; thus the benefits of dialysis would
be further limited in elderly patients combined with
dementia. These patients generally have difficulty to
express their treatment-related symptoms. In addition,
they are less likely to understand or to tolerate the dialy-
sis process [8, 10, 19–21]. Several studies, including a
recent nationwide population-based study in Taiwan,
revealed that dementia is strongly and independently
associated with morbidity and mortality not only in
the general elderly population but also in ESRD
patients [8, 10, 22–24].
Many studies have revealed that dementia and cere-
brovascular disease are related [25–27]. Accumulating
evidence from clinical, neuroimaging, and pathological
studies showed a close link between dementia and
cerebrovascular disease [25]. When examining patients
who experienced a stroke, up to 10% of these patients
already have dementia prior to the first stroke or would
suffer from dementia during the first year after the onset
of stroke [25, 28]. However, most studies exploring this
relationship between dementia and cerebrovascular
disease have been conducted exclusively in the general
population.
A recent study revealed that the presence of cardiovas-
cular disease is related to worse cognitive function in
hemodialysis (HD) patients. However, this study only
included the patients with a history of coronary disease
or peripheral vascular disease but excluded those with a
history of stroke [29]. In ESRD patients, the incidence
rate of vascular dementia is similar to or rather exceed
that of Alzheimer’s disease, which is in contrast with the
general population [30, 31]. This supports the theory
that atherosclerotic cerebrovascular disease plays a major
role in the neuropathology of dementia in ESRD patients
[3, 32]. However, there have been no studies exploring the
contribution of dementia to a composite outcome consist-
ing of mortality, cardiac events, and cerebrovascular
diseases in ESRD patients receiving HD. Therefore, this
study aimed to investigate the risk of major adverse
cardiac and cerebrovascular events (MACCE) in elderly
patients with dementia who initiate hemodialysis.
Methods
Data source and study population
The Korean Health Insurance Review and Assessment
Service (HIRA) database was used. The details of the
HIRA system were described elsewhere [33]. Data were
collected from patients aged 65 years or older who
started HD between January 1, 2005, and December 31,
2008. For incident dialysis patients, the early period,
particularly within 90 days, after dialysis initiation is
regarded as an unstable time because: 1) commonly, the
patients were on temporary renal replacement therapy
and the best dialysis modality is not yet determined; 2)
adverse events during this period are frequently affected
by various acute events, rather than by chronic intrinsic
morbidities; 3) as a frequent target of comparison, the
database for ESRD treatment provided by Medicare in
the United States Renal Data System (USRDS) during
that period was not readily available. Therefore, we
adopted the 90-day rule suggested by USRDS [34] and
only included the patients who had MACCE-free
survival within the first 90 days after initiation of dialysis
treatment. These patients were followed-up until
December 31, 2009. The comorbid conditions of partici-
pants were identified by reviewing their medical record
during a year before dialysis initiation. Mortality was
confirmed by the Certificate Database (recorded data of
reasons for changes in eligibility for National Health
Insurance or Medical Aid, death, or emigration) and the
National Health Insurance Claims Database. Other
details of organization and use of Korean HIRA Service
database were also provided elsewhere [33].
Statistical analysis
Continuous variables and categorical variables were
compared between elderly ESRD patients with and
without dementia using the independent t-test and Chi-
square test, respectively. The primary end-point of this
study was the occurrence of MACCE during follow-up.
MACCE was defined as a composite outcome of major
adverse cardiac event (MACE) and nonfatal ischemic
and hemorrhagic stroke [35]. MACE included all-cause
mortality, nonfatal acute myocardial infarction, and target
vessel revascularization, encompassing both percutaneous
coronary intervention and coronary artery bypass graft.
To assess event-free survival, the patients analyzed in this
study were left-censored for the first event-free 90 days
after dialysis initiation and were right-censored on
December 31, 2009.
The incidence rates and 95% CIs were calculated using
a Poisson distribution. The Kaplan-Meier method with
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log-rank tests was used to compare the event-free
survival of MACCE among elderly ESRD patients with
and without dementia. To identify risk factors of
MACCE, Cox proportional hazards analysis was per-
formed. The variables that have potential association
with outcome were entered in the models, including
dementia, age, sex, health insurance type, and comorbid-
ities (diabetes mellitus, myocardial infarction, congestive
heart failure, peripheral vascular disease, cerebrovascular
disease, hemiparesis, chronic pulmonary obstructive
disease (COPD), connective tissue disease, peptic ulcer
disease, liver disease, and any cancer). Clinically relevant
covariates and variables statistically significant in univar-
iate analysis were considered as candidate variables in
the multivariate Cox proportional hazard models. How-
ever, when the unadjusted and adjusted hazard ratios of
dementia in elderly ESRD dialysis patients were esti-
mated using the Cox proportional hazards model, there
were significant differences in some baseline characteris-
tics between dementia and no dementia groups. These
differences may cause biased estimates of dementia
effect on MACCE. Thus, 1:2 patient pairs with similar
propensity scores were matched to reduce biases due to
non-randomization, and further comparisons were then
performed. All P values were 2-tailed, and P < 0.05 was
considered significant. The statistical analyses were per-
formed using statistic software SPSS, version 18.0 (SPSS
Inc., Chicago, IL, USA) and R 3.1.2 (R Foundation for
statistical computing) including the Matchit package.
Results
Baseline characteristics
This study included 10,171 patients who were 65 years
or older, started HD between January 1, 2005, and
December 31, 2008, and did not experience MACCE
within 90 days from the date of dialysis initiation.
Among them, 303 patients (3.0%) were identified as
having an ICD-10 code of dementia. The prevalence
of cerebrovascular disease and hemiparesis were
higher in patients with dementia than in those with-
out dementia (P < 0.001). The median follow-up dur-
ation was 37.8 months (range of 3–84 months).
The demographic characteristics between elderly ESRD
patients with and without dementia are summarized
in Table 1.
Incidence Rates and Risk Factors of MACCE in All Elderly
Patients Starting Dialysis
During the follow-up period, 54.2% of all elderly patients
starting dialysis experienced MACCE, corresponding to
an estimated incidence rate of 343 (95% CI, 333–352)
events/1000 patient-years.
In multivariate Cox proportional hazards analysis for
delineating independent risk factors associated with
MACCE, dementia was statistically significant (HR,
1.258; 95% CI, 1.088–1.454; P = 0.002) after adjusting
confounding variables in all elderly incident HD patients
(Additional file 1: Table S1).
Table 1 Baseline characteristics of participants before and after propensity score matching
Before matching After matching
No Dementia
(n = 9,868)
Dementia
(n = 303)
P-value No Dementia
(n = 504)
Dementia
(n = 252)
P-value
Age 71.7 ± 5.3 74.6 ± 5.9 <0.001 74.5 ± 5.6 74.6 ± 5.7 0.729
Male sex 5,346 (54.2) 136 (44.9) 0.002 243 (48.2) 111 (44.0) 0.315
Health security system
National health insurance 8,840 (89.6) 261 (86.1) 0.067 446 (88.5) 214 (84.9) 0.203
Medical aid 1,028 (10.4) 42 (13.9) 58 (11.5) 384 (15.1)
Comorbidities
Diabetes 5,413 (54.9) 175 (57.8) 0.347 304 (60.3) 142 (56.3) 0.333
Cerebrovascular disease 1,521 (15.4) 131 (43.2) <0.001 223 (44.2) 107 (42.5) 0.697
Hemiparesis 152 (1.5) 15 (5) <0.001 29 (5.8) 12 (4.8) 0.691
Acute myocardial infarction 459 (4.7) 11 (3.6) 0.487 14 (2.8) 9 (3.6) 0.708
Congestive heart failure 1,829 (18.5) 70 (23.1) 0.053 115 (22.8) 60 (23.8) 0.831
Peripheral vascular disease 792 (8) 38 (12.5) 0.007 64 (12.7) 29 (11.5) 0.725
Chronic pulmonary disease 2,205 (22.3) 58 (19.1) 0.211 96 (19.5) 50 (19.8) 0.871
Connective tissue disease 314 (3.2) 7 (2.3) 0.491 9 (1.8) 4 (1.6) 1.000
Peptic ulcer disease 1,694 (17.2) 47 (15.5) 0.499 88 (17.5) 40 (15.9) 0.656
Liver disease 885 (9) 20 (6.6) 0.186 35 (6.9) 15 (6.0) 0.717
Any cancer 841 (8.5) 30 (9.9) 0.459 68 (13.5) 26 (10.3) 0.258
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Age (HR, 1.033; 95% CI, 1.028–1.038; P < 0.001), male
sex (HR, 1.106; 95% CI, 1.047–1.167; P < 0.001), medical
aid (HR, 1.215; 95% CI, 1.119–1.319; P < 0.001), and
comorbidities such as diabetes mellitus (HR, 1.201; 95%
CI, 1.137–1.268; P < 0.001), cerebrovascular disease (HR,
1.473; 95% CI, 1.374–1.579; P < 0.001), hemiparesis (HR,
1.400; 95% CI, 1.164–1.684; P < 0.001), acute myocardial
infarction (HR, 1.325; 95% CI, 1.180–1.488; P < 0.001),
congestive heart failure (HR, 1.144; 95% CI, 1.070–1.222;
P < 0.001), peripheral vascular disease (HR, 1.153; 95%
CI, 1.049–1.268; P = 0.003), chronic pulmonary disease
(HR, 1.067; 95% CI, 1.002–1.137; P = 0.045), and any
cancer (HR, 1.472; 95% CI, 1.347–1.609; P < 0.001) were
significant independent predictors of MACCE.
Risks of MACCE and its components in all elderly HD
patients with dementia
Kaplan-Meier survival curves according to dementia are
shown in Fig. 1, which were compared by the long-rank
test. The risk of MACCE was significantly higher in
patients with dementia than in those without dementia
(Fig. 1a, P < 0.001); the incidence rates of MACCE
were 559 (95% CI, 485–644) events/1000 patient-years
and 338 (95% CI, 328–347) events/1000 patient-years,
respectively.
Among the MACCE endpoints, rates of all-cause mor-
tality and ischemic stroke were significantly higher in
patients with dementia compared to patients without
dementia (Fig. 1, both Ps < 0.001), whereas rates of other
MACCE endpoints were not significantly different be-
tween patients with and without dementia (Fig. 1).
A Cox proportional hazards regression model was
performed to determine whether dementia is a signifi-
cant predictor of composite outcome and separate
components of MACCE in elderly HD patients (Table 2,
before matching). Dementia was a risk factor of MACCE
(HR, 1.258; 95% CI, 1.088–1.454; P = 0.002) and all-cause
mortality (HR, 1.334; 95% CI, 1.140–1.562; P < 0.001).
However, the statistical significance of nonfatal ischemic
stroke in the univariate analysis did not persist in multivari-
ate analysis (HR, 1.241; 95% CI, 0.931–1.654; P = 0.141).
Dementia was not significant in univariate analysis for other
individual MACCE endpoints, such as nonfatal acute
myocardial infarction, target vessel revascularization, and
nonfatal hemorrhagic stroke.
Comparison of outcomes based on estimated propensity
scores
To address concerns that the above results were affected
by a huge heterogeneity in baseline comorbid conditions
listed in Table 1 (before matching), propensity score
matching was performed to adjust for all listed baseline
differences between patients with and without dementia.
After propensity score matching, the two groups were
well matched for baseline characteristics (Table 1,
after matching).
Fig. 1 Kaplan–Meier event-free survival curves and comparisons between patients with or without dementia by log-rank test in all patients
(N = 10,171). a The incidence of MACCE was significantly higher in patients with dementia than in those without dementia (P < 0.001). b Patients
without dementia showed better survival rate than patients with dementia (P < 0.001). c-e There were no significant differences in event-free
survival rates of nonfatal acute myocardial infarction, target vessel revascularization, or nonfatal hemorrhagic stroke (P = 0.725, P = 0.236, and
P = 0.409, respectively). f However, incidence of nonfatal ischemic stroke was significantly higher in patients with dementia than in those without
dementia (P < 0.001). MACCE, major adverse cardiac and cerebrovascular event
Jung et al. BMC Nephrology  (2017) 18:128 Page 4 of 7
Kaplan-Meier survival curves (Additional file 2: Figure
S1) and hazard ratios of baseline covariates for MACCE
incidence (Additional file 1: Table S2) were estimated
using the propensity score-matched group. Dementia
was a significant predictor of MACCE (HR, 1.261; 95%
CI, 1.039; P = 0.019) (Additional file 1: Table S2). In the
analysis of individual MACCE end-points, the survival
rate was significantly higher in patients without demen-
tia than in those with dementia (Additional file 2: Figure
S1B). The incidence of ischemic stroke was significantly
lower in patients without dementia than those with
dementia (Additional file 2: Figure S1F). In multivariate
Cox proportional hazards model, dementia was an inde-
pendent predictor of nonfatal ischemic stroke (HR, 1.492;
95% CI, 1.027–2.168; P = 0.036) and all-cause mortality
(HR, 1.301; 95% CI, 1.053–1.607; P = 0.015) in propensity
score-matched pairs (Table 2, after matching).
Discussion
In this study, we investigated the risk of MACCE in
elderly Korean patients initiating HD with dementia. De-
mentia was a significant predictor of MACCE. Among
the individual endpoints of MACCE, dementia was an
independent predictor of all-cause mortality and nonfa-
tal ischemic stroke.
Several studies that examined the prevalence of cogni-
tive impairment assessed by neuropsychological tests
among ESRD patients indicate that the prevalence of
cognitive impairment ranged from 16 to 38%, depending
on characteristics of the included population [4, 5, 32,
36–40]. However, in studies that defined dementia by
reviewing medical charts or billing codes, the prevalence
of dementia was less than 15% [4, 36]. In our study, 3.2%
of elderly patients starting dialysis were diagnosed with
dementia based on a claims database. The much lower
prevalence of dementia suggests possible under-diagnosis
during the coding procedure [10]. It is well-known that
stroke and cardiovascular risk factors significantly contrib-
ute to the development of dementia [25, 41]. A consider-
able number of studies in the past 30 years have shown
the high prevalence of cognitive impairment after an onset
of stroke in the general population [25]. Post-stroke
dementia can be mediated by various mechanisms, includ-
ing vascular cognitive impairment from neuroanatomical
injuries in strategic brain regions and cerebral microbleeds
[42]. However, many aspects of the effect of stroke on
dementia are still obscure, and the effect of dementia on
stroke also remains to be elucidated. Several studies
suggest that dementia is more common in ESRD patients
than in the general population [3–7], and the risk of
stroke was also estimated to be five times higher in ESRD
patients on dialysis compared to the general population
[43]. Also, several studies revealed that the high morbidity
and mortality was observed in ESRD patients with stroke
and dementia [8, 10, 23, 24]. The relationship between
stroke and dementia in renal patients has not been well
clarified, but several studies recently indicated that vascu-
lar factors, particularly cerebrovascular disease, may play
an important role the pathogenesis of dementia in ESRD
[3, 32]. Interestingly, this close association between cogni-
tive impairment and vascular diseases was also found in
those with microalbuminuria as an early indicator of renal
damage. This was demonstrated in the study by Vupputuri
et al. in which cognitive dysfunction was only evident in
the patients with an overt vascular disease but not in those
without vascular disease [44]. The vascular structures of
the brain and kidney showed similar anatomic and
hemodynamic features in that both are end organs prone
to vascular damage because of low-resistance and frequent
exposure to a high blood flow volume [45]. Altogether,
it can be deduced that dementia and ESRD share a
common pathophysiologic process involving vascular
Table 2 Risks of major adverse cardiac and cerebrovascular events of participants before and after propensity score matching
Before matchinga After matchinga
HR (95% CI) P-value HR (95% CI) P-value
MACCE 1.258 1.088–1.454 0.002 1.261 1.039–1.531 0.019
MACE 1.285 1.101–1.499 0.001 1.204 0.979–1.480 0.078
All-cause mortality 1.334 1.140–1.562 <0.001 1.301 1.053–1.607 0.015
Non-fatal acute myocardial infarction 0.994 0.581–1.701 0.982 0.589 0.264–1.314 0.196
Target vessel revascularization 0.612 0.272–1.378 0.236 0.424 0.144–1.246 0.119
Percutaneous intervention 0.525 0.216–1.275 0.154 0.319 0.094–1.077 0.066
Coronary artery bypass graftb 1.554 0.204–1.859 0.671 – – –
Non-fatal stroke 1.134 0.856–1.501 0.382 1.326 0.923–1.904 0.127
Non-fatal hemorrhagic stroke 0.551 0.204–1.492 0.241 0.556 0.154–2.010 0.371
Non-fatal ischemic stroke 1.241 0.931–1.654 0.141 1.492 1.027–2.168 0.036
MACCE major adverse cardiac and cerebrovascular event, MACE major adverse cardiac event, HR hazard ratio CI confidence interval
aHazard ratio was adjusted for age, sex, insurance type, and comorbidities
bHR for coronary artery bypass graft was not calculated due to very low incidence
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injury in different end organs [32]. The high incidence
rate of vascular dementia in elderly HD patients was
also considered to be closely linked to advanced arterio-
sclerosis complicated by diabetes, hypertension, and rapid
blood pressure changes during HD sessions [31]. Among
other factors, atherosclerotic change and epithelium
dysfunction were reported to have an important role
in the process of cognitive impairment [22, 46].
Moreover, a recent study found that systemic athero-
sclerotic calcification, including the coronary calcifica-
tion, was another factor associated with cognitive
decline [47]. In this context, our finding that a high
incidence of cerebrovascular disease in elderly ESRD
patients with dementia can be, to some extent, ex-
plained (Table 1, before matching).
Other potential mechanisms, such as uremic toxin-
induced neuronal injury, could also account for the
development of dementia among ESRD patients. Of
note, HD itself can be implicated in the pathogenesis of
dementia via repeated exposures to rapid hemodynamic
and metabolic changes during HD sessions, which leads
to subclinical cerebral hypoperfusion, ischemia, and
edema, and ultimately can potentiate cognitive decline
[3]. This can explain why dementia is common among
elderly people with HD and is getting worse as the
duration of HD increases.
Our study has some limitations. As with other registry-
based studies, there is a possibility of coding errors or
misclassification of disease during processing of database,
which can underestimate the incidence of endpoints. In
addition, potential confounding factors for mortality such
as critical laboratory findings, inflammatory or nutritional
biomarkers, and dialysis doses were missing. However, the
strength of our study lies in that it is based on a na-
tionwide complete enumeration survey. We analyzed the
cumulative outcomes of elderly ESRD patients with or
without dementia from a large cohort that included nearly
the entire population of dialysis patients with long follow-
up periods (up to 84 months).
Conclusion
Altogether, dementia is an independent risk factor of
mortality and ischemic stroke in elderly ESRD patients
initiating HD. Patients with dementia at the initiation of
dialysis treatment should be closely monitored to reduce
the risk of mortality and ischemic stroke.
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Additional file 1: Table S1. Results of the Cox proportional hazards
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incidence of MACCE was significantly higher in patients with dementia
than those without dementia (P = 0.0304). (B) Patients without dementia
showed better survival rate compared to patients with dementia (P= 0.0348).
(C-E) There were no significant differences in event-free survival rates of
nonfatal acute myocardial infarction, target vessel revascularization,
and nonfatal hemorrhagic stroke (P = 0.31, P = 0.133, and P = 0.402,
respectively). (F) However, the incidence of nonfatal ischemic stroke
was significantly higher in patients with dementia than those without
dementia (P = 0.0492). Abbreviations: MACCE, major adverse cardiac
and cerebrovascular event. (TIF 476 kb)
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